Tag - COAG

Rodman & Renshaw initiated coverage of Hemab Therapeutics (NASDAQ: COAG) with a “buy” rating and price target of $56.00. The stock closed at $31.62 on October 9. Hemab’s lead asset sutacimig is a bispecific...